Association of Androgen Receptor Polymorphisms with Damage in SLE
雄激素受体多态性与 SLE 损伤的关联
基本信息
- 批准号:9267190
- 负责人:
- 金额:$ 5.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-05-01 至 2017-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Project Summary
Multiple genes and environmental factors likely contribute to disease susceptibility and expression in systemic
lupus erythematosus (SLE). While an understanding of the genes that contribute to the pathogenesis is far
from complete, significant progress has been made in identifying more than 40 susceptibility genes or loci.
However, much less is known about genetic factors predisposing to good outcomes in SLE. Damage in SLE,
defined by irreversible changes either as result of disease activity, therapeutic interventions or co-morbid
conditions occurring after the disease diagnosis, is measured by an instrument developed by the Systemic
Lupus International Collaborating Clinics as the SLICC/ACR damage index. Since male SLE patients tend to
develop damage earlier in the course of the illness, it is plausible that gender differences including sex
hormones, sex chromosome-linked genes and/or X chromosome inactivation (XCI) in women may play a role
in disease progression in SLE. We selected the androgen receptor gene (AR) located on the X chromosome
and tested whether shorter polyGLN polymorphisms (≤17) conferring higher androgen transactivation activity
were associated with accelerated damage in SLE. Our preliminary results of 129 men and 418 women affected
with SLE showed 1) accelerated damage in men during the first 5 years of disease especially in risk for
developing renal damage, and 2) significant associations of increased damage (SDI ≥ 2) with shorter CAG
repeat length of AR, higher cumulative prednisone dosage, and longer disease duration. These data
suggested a heightened response to testosterone and dehydroepiandrosterone (DHEA) binding mediated by
enhanced androgen transactivation activity of short CAG repeat in AR might be a prognostic marker for SLE
damage in both genders. Although DHEA has previously shown beneficial in treating SLE manifestations,
recent studies have yielded inconsistent results, highlighting the need for further studies. We hypothesize that
one or more X-linked AR variants predispose to damage accrual in SLE, and propose to assemble a
multiethnic dataset of >5,000 clinically well-characterized SLE patients containing > 500 male patients to
address whether 1) men with SLE are at risk for overall or renal damage, 2) AR variants help identify at risk
patients of both gender for damage accrual, and 3) differential levels of AR responsive gene expression
contribute to damage in SLE. Results from these studies are likely to illuminate disease mechanisms, improve
risk assessment of damage accrual, and promote consideration of selective androgen receptor modulators in
therapeutic interventions of SLE.
项目摘要
多个基因和环境因素可能导致疾病易感性和系统表达
红斑狼疮(SLE)。虽然对导致发病的基因的理解还远未达到
在鉴定40多个易感基因或位点方面取得了重大进展。
然而,对SLE中易患良好预后的遗传因素知之甚少。SLE中的损伤,
定义为疾病活动、治疗干预或合并症导致的不可逆变化
疾病诊断后发生的状况,由系统性研究所开发的仪器测量。
狼疮国际合作诊所作为SLICC/ACR损伤指数。由于男性SLE患者倾向于
在疾病的早期发展损害,这是合理的,性别差异,包括性别
女性中的激素、性染色体连锁基因和/或X染色体失活(XCI)可能起作用
在SLE疾病进展中的作用我们选择了位于X染色体上的雄激素受体基因(AR
并测试了较短的polyGLN多态性(≤17)是否赋予较高的雄激素反式激活活性,
与SLE的加速损伤有关。我们的初步结果是129名男性和418名女性受影响
1)在疾病的前5年,男性的损害加速,特别是在
发生肾损害,2)损害增加(SDI ≥ 2)与CAG缩短显著相关
AR的重复长度、较高的累积泼尼松剂量和较长的疾病持续时间。这些数据
表明对睾酮和脱氢表雄酮(DHEA)结合的反应增强,
AR中短CAG重复序列的雄激素反式激活活性增强可能是SLE的预后指标
两种性别的伤害。尽管DHEA先前已显示出对治疗SLE表现有益,
最近的研究得出了不一致的结果,突出表明需要进一步研究。我们假设
一个或多个X连锁AR变体易导致SLE中的损害累积,并提出组装一个
> 5,000例临床特征良好的SLE患者(包含> 500例男性患者)的多种族数据集,
解决1)SLE男性是否存在整体或肾损害的风险,2)AR变异有助于识别风险
两种性别的患者的损伤累积,和3)AR反应基因表达的差异水平
有助于SLE的损害。这些研究的结果可能会阐明疾病机制,改善
损害累积的风险评估,并促进考虑选择性雄激素受体调节剂,
SLE的治疗干预。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BETTY P TSAO其他文献
BETTY P TSAO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BETTY P TSAO', 18)}}的其他基金
The role of human SLE causal variant NCF1.pR90H in promoting kidney damage
人类SLE致病变异NCF1.pR90H在促进肾脏损伤中的作用
- 批准号:
10740630 - 财政年份:2023
- 资助金额:
$ 5.37万 - 项目类别:
Pathogenic role of SAT1 variants in monogenic lupus
SAT1 变异在单基因狼疮中的致病作用
- 批准号:
9920091 - 财政年份:2019
- 资助金额:
$ 5.37万 - 项目类别:
Association of Androgen Receptor Polymorphisms with Damage in SLE
雄激素受体多态性与 SLE 损伤的关联
- 批准号:
8619113 - 财政年份:2013
- 资助金额:
$ 5.37万 - 项目类别:
Association of Androgen Receptor Polymorphisms with Damage in SLE
雄激素受体多态性与 SLE 损伤的关联
- 批准号:
8738406 - 财政年份:2013
- 资助金额:
$ 5.37万 - 项目类别:
Fine Mapping and Functional Analysis of RANKL Variants in Early RA Onset
RA 早期 RANKL 变异的精细定位和功能分析
- 批准号:
7477907 - 财政年份:2007
- 资助金额:
$ 5.37万 - 项目类别:
Fine Mapping and Functional Analysis of RANKL Variants in Early RA Onset
RA 早期发病时 RANKL 变异的精细定位和功能分析
- 批准号:
7295106 - 财政年份:2007
- 资助金额:
$ 5.37万 - 项目类别:
THE ROLE OF THE PARP GENE IN SLE SUSCEPTIBILITY
PARP 基因在 SLE 易感性中的作用
- 批准号:
2902183 - 财政年份:1999
- 资助金额:
$ 5.37万 - 项目类别:
MAP THE SUSCEPTIBILITY GENE IN CHINESE SLE SIBPAIRS
绘制中国 SLE SIBP 对的易感基因图谱
- 批准号:
6188692 - 财政年份:1998
- 资助金额:
$ 5.37万 - 项目类别:
MAP THE SUSCEPTIBILITY GENE IN CHINESE SLE SIBPAIRS
绘制中国 SLE SIBP 对的易感基因图谱
- 批准号:
6078400 - 财政年份:1998
- 资助金额:
$ 5.37万 - 项目类别:
MAP THE SUSCEPTIBILITY GENE IN CHINESE SLE SIBPAIRS
绘制中国 SLE SIBP 对的易感基因图谱
- 批准号:
2695510 - 财政年份:1998
- 资助金额:
$ 5.37万 - 项目类别:
相似海外基金
Androgen Regulation of CRF Receptor 1 as a mediator of stress responses
雄激素对 CRF 受体 1 的调节作为应激反应的调节剂
- 批准号:
10724308 - 财政年份:2023
- 资助金额:
$ 5.37万 - 项目类别:
Androgen receptor: A master regulator of lipid metabolism
雄激素受体:脂质代谢的主要调节因子
- 批准号:
DP230103210 - 财政年份:2023
- 资助金额:
$ 5.37万 - 项目类别:
Discovery Projects
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
- 批准号:
10584689 - 财政年份:2023
- 资助金额:
$ 5.37万 - 项目类别:
Structural and functional analysis of a novel class of androgen receptor antagonists
一类新型雄激素受体拮抗剂的结构和功能分析
- 批准号:
10650956 - 财政年份:2023
- 资助金额:
$ 5.37万 - 项目类别:
Role of the Androgen Receptor in Insulin Secretion in the Male
雄激素受体在男性胰岛素分泌中的作用
- 批准号:
10488954 - 财政年份:2023
- 资助金额:
$ 5.37万 - 项目类别:
Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy
靶向肿瘤细胞巨噬细胞脂质相互作用以克服对雄激素受体靶向治疗的耐药性
- 批准号:
10651105 - 财政年份:2023
- 资助金额:
$ 5.37万 - 项目类别:
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
- 批准号:
10603636 - 财政年份:2023
- 资助金额:
$ 5.37万 - 项目类别:
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells
增殖细胞核抗原对去势抵抗性前列腺癌细胞雄激素受体信号传导的调节
- 批准号:
10544062 - 财政年份:2022
- 资助金额:
$ 5.37万 - 项目类别:
Effects of androgen receptor (AR) signaling on CD4+ T cell metabolism during airway inflammation
气道炎症期间雄激素受体 (AR) 信号对 CD4 T 细胞代谢的影响
- 批准号:
10534943 - 财政年份:2022
- 资助金额:
$ 5.37万 - 项目类别:














{{item.name}}会员




